PURPOSE OF REVIEW: This article discusses the central disorders of hypersomnolence, a group of disorders resulting in pathologic daytime sleepiness, particularly narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, and Kleine-Levin syndrome. Disease features, diagnostic testing, epidemiology, pathophysiology, and treatment are reviewed. RECENT FINDINGS: Increasing evidence implicates autoimmunity in narcolepsy type 1, including a strong association with human leukocyte antigen-DQB1*06:02, association with a polymorphism in the T-cell receptor alpha locus in genome-wide association, and the identification of autoreactive T cells in patients with this type of narcolepsy. In contrast, the cause or causes of narcolepsy type 2 and idiopathic hypersomnia are unknown. Multiple treatment options exist, including two medications approved for the treatment of narcolepsy by the US Food and Drug Administration (FDA) in 2019. These include solriamfetol, a dopamine- and norepinephrine-reuptake inhibitor, and pitolisant, an H3-inverse agonist/antagonist that increases histaminergic neurotransmission. SUMMARY: The central disorders of hypersomnolence all cause severe sleepiness but can be differentiated based on ancillary symptoms, diagnostic testing, and pathophysiology. It is important that these disorders are identified because multiple treatments are available to improve functioning and quality of life.
PURPOSE OF REVIEW: This article discusses the central disorders of hypersomnolence, a group of disorders resulting in pathologic daytime sleepiness, particularly narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, and Kleine-Levin syndrome. Disease features, diagnostic testing, epidemiology, pathophysiology, and treatment are reviewed. RECENT FINDINGS: Increasing evidence implicates autoimmunity in narcolepsy type 1, including a strong association with human leukocyte antigen-DQB1*06:02, association with a polymorphism in the T-cell receptor alpha locus in genome-wide association, and the identification of autoreactive T cells in patients with this type of narcolepsy. In contrast, the cause or causes of narcolepsy type 2 and idiopathic hypersomnia are unknown. Multiple treatment options exist, including two medications approved for the treatment of narcolepsy by the US Food and Drug Administration (FDA) in 2019. These include solriamfetol, a dopamine- and norepinephrine-reuptake inhibitor, and pitolisant, an H3-inverse agonist/antagonist that increases histaminergic neurotransmission. SUMMARY: The central disorders of hypersomnolence all cause severe sleepiness but can be differentiated based on ancillary symptoms, diagnostic testing, and pathophysiology. It is important that these disorders are identified because multiple treatments are available to improve functioning and quality of life.
Authors: Nathaniel F Watson; M Safwan Badr; Gregory Belenky; Donald L Bliwise; Orfeu M Buxton; Daniel Buysse; David F Dinges; James Gangwisch; Michael A Grandner; Clete Kushida; Raman K Malhotra; Jennifer L Martin; Sanjay R Patel; Stuart F Quan; Esra Tasali; Michael Twery; Janet B Croft; Elise Maher; Jerome A Barrett; Sherene M Thomas; Jonathan L Heald Journal: J Clin Sleep Med Date: 2015-06-15 Impact factor: 4.062
Authors: Mitchell G Miglis; Logan Schneider; Paul Kim; Joseph Cheung; Lynn Marie Trotti Journal: J Clin Sleep Med Date: 2020-02-10 Impact factor: 4.062
Authors: Michael J Thorpy; Colin Shapiro; Geert Mayer; Bruce C Corser; Helene Emsellem; Giuseppe Plazzi; Dan Chen; Lawrence P Carter; Hao Wang; Yuan Lu; Jed Black; Yves Dauvilliers Journal: Ann Neurol Date: 2019-03 Impact factor: 10.422
Authors: Yves Dauvilliers; Jerry M Siegel; Regis Lopez; Zoltan A Torontali; John H Peever Journal: Nat Rev Neurol Date: 2014-06-03 Impact factor: 42.937